Wall Street Is Still Positive on Nektar’s Immuno-Oncology Drug
Does Nektar's Stock Price Correction Signal a Good Opportunity? Nektar Therapeutics reported its biggest fall of ~42% on June 4 after the company reported preliminary results for its phase one and phase two trials for the company’s IO (immuno-oncology) candidate, NKTR-214, which was being evaluated in combination with Bristol Myers Squibb’s (BMY) Opdivo for the treatment of patients suffering from stage-IV metastatic melanoma, renal cell carcinoma, and urothelial cancers. BMY stock fell ~3% on the day.